非裔美国活体供者对APOL1基因检测的态度:混合方法研究
该横断面混合方法研究在单个移植中心对23名非裔美国活体供者进行半结构化访谈和问卷调查,了解其对APOL1基因检测的态度。大多数供者认为移植中心应常规提供APOL1检测,且多数愿意在捐肾前接受检测,即使携带2个高风险APOL1变异仍多愿意捐献。供者认可检测有助于知情决策,但担忧变异增加肾衰竭风险、心理困扰、保险覆盖及歧视问题。
要点
- 多数非裔美国活体供者支持移植中心常规提供APOL1基因检测。
- 多数供者愿意在捐肾前接受APOL1检测,且携带2个高风险变异仍多愿意捐献。
- 供者担忧APOL1变异增加肾衰竭风险、心理困扰及保险歧视。
核心结论
- 非裔美国供者支持APOL1基因检测,但担忧变异和检测可能对供者健康和族裔身份产生不利影响。
- 移植中心使用APOL1基因检测时应解决非裔美国供者的担忧,以优化知情同意实践。
研究设计与样本
- 横断面混合方法设计,在1个移植中心对非裔美国活体供者进行半结构化访谈和问卷调查。
- 23名供者参与半结构化访谈,访谈转录采用主题分析,调查数据采用描述性统计。
主要发现
- 96%的供者认为移植中心应常规向所有非裔美国潜在供者提供APOL1基因检测。
- 87%的供者愿意在捐肾前接受APOL1检测。
- 61%的供者即使携带2个高风险APOL1变异仍愿意捐献。
- 供者认为APOL1检测有助于提供信息以帮助供者做出知情捐献决定。
- 供者担忧APOL1变异使供者面临肾衰竭风险、心理困扰、保险覆盖和费用问题以及可能对非裔美国人的歧视。
临床怎么用
- 移植中心在实施APOL1基因检测时,应针对非裔美国供者的担忧进行沟通,以优化知情同意。
局限性
- 研究结果可能无法推广至非裔美国潜在供者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: African American live kidney donors ("donors") have a greater risk for kidney failure than European American donors. Apolipoprotein L1 gene (APOL1) variants in African Americans may be associated with this disparity. STUDY DESIGN: Cross-sectional mixed-methods design. SETTING & PARTICIPANTS: African American donors at 1 transplantation center. ANALYTICAL APPROACH: Semistructured interviews assessed attitudes about APOL1 genetic testing, willingness to undergo APOL1 testing, hypothetical decisions about donating with 2 APOL1 variants, and demographics. Surveys assessed perceptions of ethnic identity and genetics knowledge. Interview transcriptions were analyzed using thematic analysis. Survey data were analyzed using descriptive statistics. RESULTS: 23 donors participated in semistructured interviews. Most (96%) reported that transplantation centers should routinely offer APOL1 genetic testing to all African American potential donors. Most (87%) would have been willing to undergo APOL1 testing before donating. Although study participants noted that APOL1 testing may deter African American potential donors from donating, most (61%) would have donated even if they had 2 high-risk APOL1 variants. Several themes emerged. Study participants believed that APOL1 testing was beneficial for providing information to help donors make informed donation decisions. Participants expressed concern about APOL1 variants placing donors at harm for kidney failure, and therefore valued taking preventive health measures. Participants believed that potential donors would experience psychological distress from learning that they have 2 gene variants and could harm their recipients. Participants were apprehensive about insurance coverage and costs of APOL1 testing and feared that APOL1 genetic test results could discriminate against African Americans. LIMITATIONS: Findings may not be generalizable to African American potential donors. CONCLUSIONS: Findings suggest that African American donors support APOL1 genetic testing yet fear that APOL1 variants and genetic testing could adversely affect donors' health and ethnic identity. Transplantation centers using APOL1 genetic testing should address African American donors' concerns about APOL1 genetic testing to optimize future donors' informed consent practices.
引用
- Gordon EJ, Amόrtegui D, Blancas I, et al. African American Living Donors' Attitudes About APOL1 Genetic Testing: A Mixed Methods Study. Am J Kidney Dis. 2018. PMID: 30360961. doi:10.1053/j.ajkd.2018.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。